Alexion Pharmaceuticals (ALXN) Shares are Down -2.68%

Alexion Pharmaceuticals (ALXN) has risen sharply, recording gains of 6.26% in the past 4 weeks. However, the stock has corrected -2.68% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 5.17% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 2.14% and the 50-Day Moving Average is 3.53%. Alexion Pharmaceuticals (NASDAQ:ALXN): On Fridays trading session , Opening price of the stock was $132.94 with an intraday high of $133.5. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $131.31. However, the stock managed to close at $133.44, a loss of 0.17% for the day. On the previous day, the stock had closed at $133.67. The total traded volume of the day was 1,096,222 shares.


The company Insiders own 4.41% of Alexion Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.34% . Institutional Investors own 97.45% of Alexion Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -25.58%. Also, In the latest statement by the brokerage house, Barclays maintains its outlook on Alexion Pharmaceuticals (NASDAQ:ALXN). The current rating of the shares is Equal-weight, according to the research report released by the firm. The brokerage firm lowers the price target from $165 per share to $150 per share. The rating by the firm was issued on July 29, 2016.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *